New Chemo-Light cocktail offers hope for elderly lymphoma patients
NCT ID NCT05798156
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a chemotherapy-light combination of three drugs—rituximab, polatuzumab vedotin, and glofitamab—in 125 patients over 60 with aggressive B-cell lymphoma who cannot tolerate full-dose standard chemo. The goal is to see if this gentler approach can control the disease and improve survival without harsh side effects. Results will guide future development of this treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rituximab, polatuzumab vedotin, and glofitamab
What this could lead to
If successful, this could offer a gentler, effective treatment option for older or frail patients with aggressive B-cell lymphoma who cannot handle standard chemotherapy.
What could go wrong
This is a phase 2 trial with only 125 participants, so results are preliminary. The combination may not work as well as hoped, and side effects from the drugs could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AKH Meduni Wien
Vienna, Austria
-
Charité - Universitätsmedizin Berlin
Berlin, Germany
-
Ev. Klinikum Essen-Mitte
Essen, Germany
-
HELIOS Klinikum Berlin-Buch
Berlin, Germany
-
Hanusch Krankenhaus
Vienna, Austria
-
Kepler Universitätsklinikum
Linz, Austria
-
Klinikum Chemnitz
Chemnitz, Germany
-
Klinikum Ludwigshafen
Ludwigshafen, 67063, Germany
-
Kreiskliniken Reutlingen
Reutlingen, Germany
-
Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Salzburg, Austria
-
Medizinisches Universitätsklinikum Knappschaftskrankenhaus Bochum
Bochum, Germany
-
Ordensklinikum Linz - Barmherzige Schwestern
Linz, Austria
-
Ordensklinikum Linz - Elisabethinen
Linz, Austria
-
Ortenauklinikum Offenburg-Kehl
Offenburg, Germany
-
TU München (rechts des Isar)
München, Germany
-
Uniklinik Innsbruck
Innsbruck, Austria
-
Uniklinikum Düsseldorf
Düsseldorf, Germany
-
Univ. Klinikum St. Pölten
Sankt Pölten, Austria
-
University Hospital Jena
Jena, Germany
-
Universitätsklinikum Erlangen
Erlangen, Germany
-
Universitätsklinikum Halle
Halle, Germany
-
Universitätsklinikum Leipzig
Leipzig, 04103, Germany
-
Universitätsklinikum Magdeburg
Magdeburg, Saxony-Anhalt, 39120, Germany
-
Universitätsklinikum Regensburg
Regensburg, Germany
-
Universitätsklinikum Schleswig-Holstein Campus Kiel
Kiel, Germany
-
Universitätsklinikum Würzburg
Würzburg, Germany
-
Unversitätsklinikum Münster
Münster, 48149, Germany
-
Westdeutsches Tumorzentrum Essen
Essen, Germany